Sorafenib in Patients With Hepatopulmonary Syndrome: A Double-Blind Randomized Clinical Trial

Trial Profile

Sorafenib in Patients With Hepatopulmonary Syndrome: A Double-Blind Randomized Clinical Trial

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver disorders; Lung disorders
  • Focus Therapeutic Use
  • Acronyms SHPS
  • Most Recent Events

    • 05 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
    • 05 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 05 Jul 2016 Planned number of patients changed from 50 to 30.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top